Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The European Union and drugs]

G Viala1, M D Campion

  • 1UFR de Pharmacie, Aix-Marseille II.

Annales Pharmaceutiques Francaises
|January 1, 1995
PubMed
Summary

The European Union

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Access of developing countries to essential drugs: a process of equity].

Bulletin de l'Academie nationale de medecine·2002
Same author

[Pharmacists in code of public health].

Revue d'histoire de la pharmacie·2001
Same author

["Frontier" products].

Annales pharmaceutiques francaises·1999
Same author

Effect of posture on the onset of fictive locomotion in the decerebrate rabbit preparation.

Neuroscience letters·1996
Same author

Interneurones of the lumbar cord related to spontaneous locomotor activity in the rabbit. I. Rhythmically active interneurones.

Experimental brain research·1991
Same author

Reflex modulation of phrenic activity through hindlimb passive motion in decorticate and spinal rabbit preparation.

Neuroscience·1988

Area of Science:

  • EU pharmaceutical policy
  • Regulatory harmonization
  • Internal market development

Context:

  • 1993 marked the EU's Internal Market and Economic Union Treaties.
  • International Council for Harmonisation (ICH) standards guide scientific and technical harmonization.
  • EU competencies in Research, Industrial Policy, and Environment foster innovation.

Purpose:

  • To analyze the European Union's regulatory framework for medicinal products post-1993.
  • To examine the impact of EU policies on pharmaceutical innovation and market access.
  • To understand the balance between EU-level harmonization and Member State flexibility.

Summary:

  • The EU's 1993 treaties established a new era for medicinal products, integrating scientific harmonization via ICH guidelines.
  • Broader EU competencies in research and industry promote innovation, competition, and alignment with the European Medicines Agency.
  • Member State autonomy in public health and social security allows for consumer-centric flexibility, reflecting diverse socio-cultural norms.

Impact:

  • The EU's approach facilitates pharmaceutical innovation and market competition.
  • Harmonization at the EU level streamlines regulatory processes for medicinal products.
  • Subsidiarity ensures that national specificities in public health are respected, benefiting consumers.

Related Experiment Videos